Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Selective induction of PYROptosis in acute myeloid leukemia cells with VECTORized DPP9 inhibitors

Obiettivo

DPP9 (dipeptidyl peptidase 9) is a cytosolic serine protease. It recognizes and cleaves N-terminal dipeptides containing proline at the penultimate position. The enzyme is currently receiving strong international attention after it was reported that DPP9 inhibition induces inflammatory cell death (pyroptosis) in Acute Myeloid Leukemia (AML) cells. Pyroptosis is a lytic form of cell death that also causes a pronounced, local upregulation of the innate immune system. This is of particular interest to leukemia treatment because the immune response to leukemic cells is strongly suppressed. Very recently, however, reports have been published that identify other, non-cancerous cell types that also undergo pyroptosis upon DPP9 inhibition. This raises questions on how selective and safe DPP9 inhibition can be as a therapeutic strategy in AML. The host reported the first selective, nanomolar DPP9 inhibitors in 2023 and also discovered the first DPP9-degrading PROTACs (unpublished data). PyroVector’s mission is to selectively unleash these molecules’ pyroptosis induction potential against AML cells, by delivering them towards these cells with vector approaches. Given the general lack of knowledge on how to optimally target small molecules to AML cells, three molecules that recognize AML cells will be compared as vectors for DPP9 inhibitors: a monoclonal antibody, an AML cell-penetrating peptide, and a sialic acid analog. DPP9 inhibitors that are covalently linked to these 3 ligands, will be investigated in terms of internalization and pyroptosis induction in cells. Furthermore, AML selectivity and therapeutic potential in vivo will be characterized with the ultimate aim of validating the approach as a safe and effective therapeutic strategy for AML. Overall we are strongly convinced that this project can be an essential step toward a patient-friendly application of DPP9 inhibition or degradation in AML.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-MSCA-2023-PF-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

UNIVERSITEIT ANTWERPEN
Contributo netto dell'UE
€ 191 760,00
Indirizzo
PRINSSTRAAT 13
2000 Antwerpen
Belgio
Regione
Vlaams Gewest Prov. Antwerpen Arr. Antwerpen
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
Nessun dato